ClinicalTrials.gg
CompletedNCT04405570Updated Feb 16, 2022Results posted

Safety, Tolerability and Efficacy of Molnupiravir (EIDD-2801) to Eliminate Infectious Virus Detection in Persons With COVID-19

A Phase 2 interventional study of Molnupiravir 200 mg and Molnupiravir 400 mg in SARS-CoV-2 Infection, COVID-19, sponsored by Ridgeback Biotherapeutics, LP. Completed at 10 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-02-16.

Sponsored by Ridgeback Biotherapeutics, LP · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
204
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies testing molnupiravir in COVID-19 — 4 open to participants now, 4 under way, 2 of them phase 3. molnupiravir · COVID-19.

Enrollment
10th of 14
204 · median 275
Started
2020
with 4 others
Phase 2
2 of 14
1 open now
Registered
2nd of 14
by date
Lead sponsor
1 of 14
Ridgeback Biotherapeutics, LP

Among the 14 studies testing molnupiravir in COVID-19, this one is the 10th largest by enrollment, is one of 5 that started in 2020, is one of 2 in phase 2, and was the 2nd registered.

COVID-19

7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.

Browse COVID-19 studies →

Open to participants now

4 of the 14 studies testing molnupiravir in COVID-19 are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About molnupiravir

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing molnupiravir in COVID-19, or all of them as a file.
02

Study summary

This was a phase IIa, double-blind, placebo-controlled, randomized trial, designed to compare the safety, tolerability, and antiviral activity of EIDD-2801 (molnupiravir) versus placebo as measured by SARS-CoV-2 viral RNA detection in symptomatic adult outpatients with COVID-19.

Read the detailed description

This was a phase IIa, double-blind, placebo-controlled, randomized trial, designed to compare the safety, tolerability, and antiviral activity of molnupiravir versus placebo as measured by SARS-CoV-2 viral RNA detection in symptomatic adult outpatients with COVID-19. The study was a multicenter trial that was conducted in the United States.

In this study, 204 participants were randomized and 202 received molnupiravir or placebo orally twice a day (BID) for 5 days. The study enrolled participants in 5 parts with each part evaluating molnupiravir doses of either 200 mg BID, 400 mg BID, or 800 mg BID. Doses were chosen based on emerging virology and safety data from this and ongoing studies. New dose groups were started after the selected dose had been studied for safety in a Phase 1 study.

03

Conditions studied

  • SARS-CoV-2 Infection, COVID-19

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Able to provide prior to initiation of any study procedures.
  2. ≥18 years of age at Screening.
  3. Study treatment is expected to begin within ≤168 hours from first symptom onset.
  4. Ability to swallow pills.
  5. Documentation of confirmed active SARS-CoV-2 infection, as determined by a molecular or non-molecular ("rapid") test conducted at any clinic or laboratory that had a Clinical Laboratory Improvement Amendments (CLIA) certification or its equivalent from a sample collected ≤96 hours prior to study entry.
  6. Was experiencing at least one of the following SARS-CoV-2 infection symptoms at the time of enrollment: fever (could be subjective including feeling feverish or having chills) OR signs/symptoms of respiratory illness (including but not limited to upper respiratory congestion, loss of sense of smell or taste, sore throat OR lower respiratory illness - cough, shortness of breath).
  7. Agreed to not participate in another interventional clinical trial for the treatment of SARS-CoV-2 during the study period (28 days) unless hospitalized.
  8. Agreed to not obtain medications outside of the molnupiravir study.
  9. Agreed to the sampling detailed in the schedule of evaluations and to comply with study requirements including requirements.
  10. A female participant was eligible to participate if she was not pregnant or breastfeeding and at least one of the following conditions applied:

    • Was not a woman of (WOCBP) OR
    • Was a WOCBP and using a contraceptive method that is highly effective (a low user dependency method OR a user-dependent method in combination with a barrier method), or was abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long-term and persistent basis), as described in Appendix 2 of the study protocol during the intervention period and for at least 50 days after the last dose of study intervention. The investigator evaluated the potential for contraceptive method failure (ie, noncompliance, recently initiated) in relationship to the first dose of study intervention.
    • A WOCBP must have had a negative highly sensitive pregnancy test (serum or urine) within 24 hours before the first dose of study intervention.
    • Additional requirements for pregnancy testing during and after study intervention were provided in the study protocol.
    • The investigator was responsible for review of medical history, menstrual history, and recent sexual activity to decrease the risk for inclusion of a woman with an early undetected pregnancy.
    • Contraceptive use by women was to be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
    • Given the elevated risk of venous thrombotic events in patients hospitalized with COVID-19 (Benson et al, 2020; Spratt et al, 2020), estrogen-containing contraceptives could not be started to fulfill the contraceptive requirement of this study at any time during participant's participation. If contraceptives were interrupted as standard of care management of COVID-19 patients and resumed at a later time point, such as at hospital discharge, then abstinence was practiced for the defined period of back-up contraception per the contraceptive product labeling. After this period, contraceptive use had to adhere to the guidance in Appendix 2 of the study protocol.
  11. Male participants were eligible to participate if they agreed to the following during the intervention period and for at least 100 days after the last dose of study intervention:

    • Refrained from donating sperm

PLUS either:

  • Were abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis) and agreed to remain abstinent.

OR

  • Had to agree to use contraception unless confirmed to be azoospermic (vasectomized or secondary to medical cause [Appendix 2 of the study protocol]) as detailed below:

    • Agreed to use a male condom plus partner use of an additional contraceptive method when having penile-vaginal intercourse with a WOCBP who was not pregnant. Note: Men with a pregnant or breastfeeding partner had to agree to remain abstinent from penile-vaginal intercourse or use a male condom during each episode of penile-vaginal penetration.
    • Contraceptive use by men was to be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.

Exclusion criteria

Exclusion Criteria:

  1. Need for hospitalization or immediate medical attention in the clinical opinion of the study investigator.
  2. \<10 g/dL in men and \<9 g/dL in women.
  3. count \<100,000/ µL or received a platelet transfusion within 5 days prior to enrollment.
  4. Was on dialysis or has an estimated \<30 mL/min/1.73 m\^2
  5. (AST)/alanine aminotransferase (ALT) >3x upper limit normal ().
  6. History of or current hospitalization for COVID-19. Note: Individuals hospitalized and then discharged, even if only hospitalized for 1 day, were excluded.
  7. History of kidney disease as evidenced by estimated value \<30 mL/min.
  8. History of significant liver disease in the opinion of the site investigator or active or active . (HIV) that is advanced (CD4\<200/mm\^3) and/or on treatment with nucleos(t)ide analogues.
  9. Use of therapeutic interventions with possible anti-SARS-CoV-2 activity within 30 days prior to study entry, (e.g., remdesivir, lopinavir/ritonavir fixed dose combination, ribavirin, chloroquine, hydroxychloroquine, and convalescent plasma), or participation in a clinical trial involving any of these drugs whether for treatment or prophylaxis.
  10. Receipt of a SARS-CoV-2 vaccination prior to study entry.
  11. Known allergy/sensitivity or any to components of molnupiravir, or its formulation.
  12. Active drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements.
  13. History of recent (within the past 3 months) hemorrhagic cerebrovascular accident) or major bleed.
  14. Presence of a condition, that in the opinion of the investigator, would place the subject at increased risk from study participation.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
204 participants (actual)

Study arms

  • Experimental
    Molnupiravir 200 mg

    Molnupiravir 200 mg, twice daily (BID) for 5 days

    Drug: Molnupiravir 200 mg

  • Experimental
    Molnupiravir 400 mg

    Molnupiravir 400 mg, twice daily (BID) for 5 days

    Drug: Molnupiravir 400 mg

  • Experimental
    Molnupiravir 800 mg

    Molnupiravir 800 mg, twice daily (BID) for 5 days

    Drug: Molnupiravir 800 mg

  • Placebo comparator
    Placebo (PBO) twice daily (BID) for 5 days

    Drug: Placebo (PBO)

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants Until First Non-detectable SARS-CoV-2 in Nasopharyngeal (NP) Swabs

    The number of participants until first non-detectable SARS-CoV-2 in nasopharyngeal (NP) swabs will be estimated for each randomized arm (drug versus placebo), using Kaplan-Meier methods with a corresponding log-rank test. Non detectable defined as "a viral load below the limit of quantification

    Time frame: 28 days

  2. Time to Clearance of SARS-CoV-2 in Nasopharyngeal Swabs

    The distribution of days until first non-detectable SARS-CoV-2 in nasopharyngeal (NP) swabs will be estimated for each randomized arm (drug versus placebo), using Kaplan-Meier methods with a corresponding log-rank test. Non detectable defined as "a viral load below the limit of quantification

    Time frame: 28 days

  3. Number of Participants With Adverse Events (AEs) Grade 3 or Higher or Leading to Discontinuation of Study Treatment

    1) any AEs leading to early discontinuation of blinded treatment (active or placebo), 2) study drug-related discontinuation of treatment, 3) new grade 3 or higher AEs (not already present at baseline), and 4) study drug-related new grade 3 or higher AEs.

    Time frame: 28 days

Secondary outcomes

  1. Number of Participants With Any Adverse Events (AEs), Grade 2 or Higher

    Measure the safety and tolerability of EIDD-2801 by estimating the occurrence of Grade 2 or higher AE and drug related AEs.

    Time frame: 28 days

07

Results

Posted Feb 16, 2022

Participant flow

Participant flow — Overall Study
MilestoneMolnupiravir 200 mgMolnupiravir 400 mgMolnupiravir 800 mgPlacebo
Started23645562
Number of subjects randomized not dosed0200
Number of subjects in the safety population23625562
Number of subjects in the mitt population23615361
Completed23595261
Not completed0531
Withdrew: Adverse event0111
Withdrew: Lost to follow-up0100
Withdrew: Physician decision0010
Withdrew: Withdrawal by subject0110
Withdrew: Randomized not dosed0200

Outcome measures

PrimaryNumber of Participants Until First Non-detectable SARS-CoV-2 in Nasopharyngeal (NP) Swabs

The number of participants until first non-detectable SARS-CoV-2 in nasopharyngeal (NP) swabs will be estimated for each randomized arm (drug versus placebo), using Kaplan-Meier methods with a corresponding log-rank test. Non detectable defined as "a viral load below the limit of quantification

Time frame:
28 days
Reported as:
Count of participants · Participants
Number of Participants Until First Non-detectable SARS-CoV-2 in Nasopharyngeal (NP) Swabs
ParticipantsMolnupiravir 200 mgMolnupiravir 400 mgMolnupiravir 800 mgPlacebo
Number (%) with response21484949
Number (%) censored213412
Statistical analysis
  • Molnupiravir 200 mg · Log Rank · p = 0.5551
  • Molnupiravir 400 mg · Log Rank · p = 0.7270
  • Molnupiravir 800 mg · Log Rank · p = 0.0128
PrimaryTime to Clearance of SARS-CoV-2 in Nasopharyngeal Swabs

The distribution of days until first non-detectable SARS-CoV-2 in nasopharyngeal (NP) swabs will be estimated for each randomized arm (drug versus placebo), using Kaplan-Meier methods with a corresponding log-rank test. Non detectable defined as "a viral load below the limit of quantification

Time frame:
28 days
Reported as:
Median · Days
Time to Clearance of SARS-CoV-2 in Nasopharyngeal Swabs
DaysMolnupiravir 200 mgMolnupiravir 400 mgMolnupiravir 800 mgPlacebo
Time to Clearance of SARS-CoV-2 in Nasopharyngeal Swabs22.0 (15.0 to 28.0)27.0 (15.0 to 28.0)14.0 (13.0 to 14.0)15.0 (15.0 to 27.0)
PrimaryNumber of Participants With Adverse Events (AEs) Grade 3 or Higher or Leading to Discontinuation of Study Treatment

1) any AEs leading to early discontinuation of blinded treatment (active or placebo), 2) study drug-related discontinuation of treatment, 3) new grade 3 or higher AEs (not already present at baseline), and 4) study drug-related new grade 3 or higher AEs.

Time frame:
28 days
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs) Grade 3 or Higher or Leading to Discontinuation of Study Treatment
ParticipantsMolnupiravir 200 mgMolnupiravir 400 mgMolnupiravir 800 mgPlacebo
AEs leading to early discontinuation of blinded treatment (active or placebo)0111
AEs leading to study drug-related discontinuation of treatment0000
new grade 3 or higher AEs (not already present at baseline)1245
study drug-related new grade 3 or higher AEs0000
SecondaryNumber of Participants With Any Adverse Events (AEs), Grade 2 or Higher

Measure the safety and tolerability of EIDD-2801 by estimating the occurrence of Grade 2 or higher AE and drug related AEs.

Time frame:
28 days
Reported as:
Count of participants · Participants
Number of Participants With Any Adverse Events (AEs), Grade 2 or Higher
ParticipantsMolnupiravir 200 mgMolnupiravir 400 mgMolnupiravir 800 mgPlacebo
Number of Participants With Any Adverse Events (AEs), Grade 2 or Higher5769

Adverse events

Collected over 28 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Molnupiravir 200 mg0/23 (0%)0/23 (0%)4/23 (17.4%)
Molnupiravir 400 mg0/62 (0%)2/62 (3.2%)2/62 (3.2%)
Molnupiravir 800 mg0/55 (0%)1/55 (1.8%)1/55 (1.8%)
Placebo0/62 (0%)1/62 (1.6%)4/62 (6.5%)
Most frequent serious events
Most frequent serious events
EventMolnupiravir 200 mgMolnupiravir 400 mgMolnupiravir 800 mgPlacebo
Acute respiratory failureRespiratory, thoracic and mediastinal disorders0/230/621/550/62
Oxygen saturation decreasedInvestigations0/231/620/550/62
HypoxiaRespiratory, thoracic and mediastinal disorders0/230/620/551/62
Cerebrovascular accidentNervous system disorders0/231/620/550/62
Most frequent other events
Most frequent other events
EventMolnupiravir 200 mgMolnupiravir 400 mgMolnupiravir 800 mgPlacebo
DizzinessNervous system disorders2/231/620/550/62
InsomniaPsychiatric disorders2/231/621/554/62

Baseline characteristics

Age, Continuous
Age, Continuous(years)Molnupiravir 200 mgMolnupiravir 400 mgMolnupiravir 800 mgPlaceboTotal
Mean36.5 ± 15.3442.4 ± 14.8842.2 ± 14.3639.7 ± 14.1040.8 ± 14.57
Sex: Female, Male
Sex: Female, Male(Participants)Molnupiravir 200 mgMolnupiravir 400 mgMolnupiravir 800 mgPlaceboTotal
Female11322734104
Male1230282898
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Molnupiravir 200 mgMolnupiravir 400 mgMolnupiravir 800 mgPlaceboTotal
Hispanic or Latino723332386
Not Hispanic or Latino16392139115
Unknown or Not Reported00101
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Molnupiravir 200 mgMolnupiravir 400 mgMolnupiravir 800 mgPlaceboTotal
American Indian or Alaska Native00000
Asian12126
Black or African American333211
White17564954176
Other20215
Multiple01034
08

Study locations

10 sites
  • Valley Clinical Trials, Inc.
    Northridge, California 91325, United States
  • FOMAT Medical Research
    Oxnard, California 93030, United States
  • Southern California Emergency Medicine
    Yucaipa, California 92399, United States
  • Indago Research and Health Center, Inc.
    Hialeah, Florida 33012, United States
  • NOLA Research Works, LLC
    New Orleans, Louisiana 70115, United States
  • University of North Carolina School of Medicine
    Chapel Hill, North Carolina 27599, United States
  • Duke University Medical Center
    Durham, North Carolina 27710, United States
  • Wake Forest Baptist Medical Center
    Winston-Salem, North Carolina 27157, United States
  • Care United Research, LLC
    Forney, Texas 75126, United States
  • Fred Hutchinson Cancer Research Center
    Seattle, Washington 98109, United States
09

References and documents

Publications

  • Mollan KR, Eron JJ, Krajewski TJ, Painter W, Duke ER, Morse CG, Goecker EA, Premkumar L, Wolfe CR, Szewczyk LJ, Alabanza PL, Loftis AJ, Degli-Angeli EJ, Brown AJ, Dragavon JA, Won JJ, Keys J, Hudgens MG, Fang L, Wohl DA, Cohen MS, Baric RS, Coombs RW, Sheahan TP, Fischer WA. Infectious Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Virus in Symptomatic Coronavirus Disease 2019 (COVID-19) Outpatients: Host, Disease, and Viral Correlates. Clin Infect Dis. 2022 Aug 24;75(1):e1028-e1036. doi: 10.1093/cid/ciab968. PubMed 35022711 ↗
  • Fischer W, Eron JJ, Holman W, Cohen MS, Fang L, Szewczyk LJ, Sheahan TP, Baric R, Mollan KR, Wolfe CR, Duke ER, Azizad MM, Borroto-Esoda K, Wohl DA, Loftis AJ, Alabanza P, Lipansky F, Painter WP. Molnupiravir, an Oral Antiviral Treatment for COVID-19. medRxiv [Preprint]. 2021 Jun 17:2021.06.17.21258639. doi: 10.1101/2021.06.17.21258639. PubMed 34159342 ↗
  • Mollan KR, Eron JJ, Krajewski TJ, Painter W, Duke ER, Morse CG, Goecker EA, Premkumar L, Wolfe CR, Szewczyk LJ, Alabanza PL, Loftis AJ, Degli-Angeli EJ, Brown AJ, Dragavon JA, Won JJ, Keys J, Hudgens MG, Fang L, Wohl DA, Cohen MS, Baric RS, Coombs RW, Sheahan TP, Fischer WA 2nd. Infectious SARS-CoV-2 Virus in Symptomatic COVID-19 Outpatients: Host, Disease, and Viral Correlates. medRxiv [Preprint]. 2021 Jun 25:2021.05.28.21258011. doi: 10.1101/2021.05.28.21258011. PubMed 34100024 ↗
  • Cox RM, Wolf JD, Plemper RK. Therapeutically administered ribonucleoside analogue MK-4482/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets. Nat Microbiol. 2021 Jan;6(1):11-18. doi: 10.1038/s41564-020-00835-2. Epub 2020 Dec 3. PubMed 33273742 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — There is not a plan to make IPD available.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2020 to primary completion in Feb 2021, 8 months.

Results were first posted in Feb 2022, 11 months after primary completion.

Of 224 industry-sponsored phase 2 interventional studies under COVID-19, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 13. This study's 8 months is close to that.

Counting every sponsor, half of 583 studies reached it within 9 months; a quarter within 5 and three quarters within 16.

How these figures are worked out, and which studies are left out of them.

Registered
May 26, 2020
First posted
May 28, 2020
StartActual
Jun 19, 2020
Primary completionActual
Feb 21, 2021
CompletionActual
Feb 21, 2021
Results first posted
Feb 16, 2022
Last update
Feb 16, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 16, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04405570
Lead sponsor
Ridgeback Biotherapeutics, LP
Responsible party
Sponsor
First posted
May 28, 2020
Start date
Jun 19, 2020
Primary completion
Feb 21, 2021
Completion
Feb 21, 2021
Results posted
Feb 16, 2022
Last update
Feb 16, 2022

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Molnupiravir

Start the discussion